PIII vs. XGN, DCGO, CORBF, SERA, QIPT, BNR, BDSX, ATPC, EUDA, and BMGL
Should you be buying P3 Health Partners stock or one of its competitors? The main competitors of P3 Health Partners include Exagen (XGN), DocGo (DCGO), Global Cord Blood (CORBF), Sera Prognostics (SERA), Quipt Home Medical (QIPT), Burning Rock Biotech (BNR), Biodesix (BDSX), Agape ATP (ATPC), EUDA Health (EUDA), and Basel Medical Group (BMGL). These companies are all part of the "healthcare" industry.
P3 Health Partners vs. Its Competitors
P3 Health Partners (NASDAQ:PIII) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.
P3 Health Partners presently has a consensus target price of $16.25, suggesting a potential upside of 86.46%. Exagen has a consensus target price of $12.00, suggesting a potential upside of 28.89%. Given P3 Health Partners' higher probable upside, research analysts clearly believe P3 Health Partners is more favorable than Exagen.
Exagen has lower revenue, but higher earnings than P3 Health Partners. Exagen is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.
7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 17.8% of P3 Health Partners shares are held by insiders. Comparatively, 12.6% of Exagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
P3 Health Partners has a net margin of -9.99% compared to Exagen's net margin of -28.85%. Exagen's return on equity of -130.38% beat P3 Health Partners' return on equity.
P3 Health Partners has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Exagen has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500.
In the previous week, Exagen had 18 more articles in the media than P3 Health Partners. MarketBeat recorded 21 mentions for Exagen and 3 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 1.28 beat Exagen's score of 1.00 indicating that P3 Health Partners is being referred to more favorably in the media.
Summary
Exagen beats P3 Health Partners on 9 of the 16 factors compared between the two stocks.
Get P3 Health Partners News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIII and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PIII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
P3 Health Partners Competitors List
Related Companies and Tools
This page (NASDAQ:PIII) was last updated on 9/16/2025 by MarketBeat.com Staff
